Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3669 | Sofosbuvir/Daclatasvir Wiki | 1.00 |
| drug2552 | Nitazoxanide Wiki | 0.26 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a multi-site, prospective, non-randomised trial assessing the implementation of a smartphone application-based model of care for patients with COVID-19 infection managed in community isolation. We will recruit 2000 COVID +ve patients aged 18 years and over who are managed at home. The objective will be to describe the rates of avoidable presentations to ED and 30 day all case mortality per diagnosed COVID-19 case and to compare these to a propensity matched and synthetic control group.
Description: Definition based on potentially avoidable general practitioner-type presentations as specified in the National Healthcare
Measure: Rate of avoidable Emergency Department presentations per diagnosed COVID-19 case Time: 12 monthsDescription: Data linkage to patient medical records
Measure: Rate of hospital admission per diagnosed COVID case Time: 12 monthsDescription: Data linkage to MBS database and patient medical records
Measure: Rate of MBS claims for un-referred visits to general practitioners and analogous COVID-19 MBS telehealth items per diagnosed COVID case Time: 12 monthsDescription: Data linkage to patient medical records
Measure: Average length of stay (LOS) for admitted patients per diagnosed COVID case Time: 12 monthsDescription: Data linkage to patient medical records
Measure: Rate of admission to Intensive Care Unit (ICU) for admitted patients per diagnosed COVID case Time: 12 monthsDescription: Data linkage to patient medical records
Measure: Time from presentation to admission to ICU for patients admitted to ICU per diagnosed COVID case Time: 12 monthsDescription: Data linkage to patient medical records
Measure: Rate of intubation in admitted patients per diagnosed COVID case Time: 12 monthsDescription: Data linkage to patient medical records
Measure: Rate of readmission within 30 days of discharge in admitted patients per diagnosed COVID case Time: 30 daysDescription: Data linkage to patient medical records
Measure: Rate of avoidable Emergency Department presentations with COVID-19 diagnosis per 100,000 population, during trial period Time: 12 monthsDescription: Data linkage to patient medical records
Measure: Rate of hospital admission with COVID-19 diagnosis per 100,000 population, during trial period Time: 12 monthsDescription: Data linkage to patient medical records
Measure: Rate of admission to ICU with COVID-19 diagnosis per 100,000 population during trial period Time: 12 monthsDescription: Data linkage to patient medical records
Measure: Rate of mortality with COVID-19 cause of death per 100,000 population, during trial period Time: 12 monthsDescription: The feedback questionnaire was designed specifically for this study.
Measure: Qualitative assessment of TCC-COVID app usability via a subjective feedback questionnaire provided to all patients enrolled in the study. Time: 12 monthsDescription: From NSW Health data linkage
Measure: Cost-effectiveness of TCC-COVID by measuring the incremental cost per death averted, per ICU admission averted and per length of stay in ICU Time: 12 monthsDescription: Data linkage to patient medical records
Measure: Rate of hospital bed days with COVID-19 diagnosis per 100,000 population, during trial period Time: 12 monthsDescription: Data linkage to patient medical records
Measure: Rate of ICU bed days with COVID-19 diagnosis per 100,000 population, during trial period Time: 12 monthsDescription: Completed by all physicians and research nurses entering data into the portal and monitoring patients throughout the study. The feedback questionnaire was designed specifically for this study.
Measure: Qualitative assessment of KIOLA physician portal usability via a subjective feedback questionnaire Time: 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports